● Recruiting

Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia

Condition: AML, Adult · Sponsor: Zhejiang University

PhasePhase 1

Planned participants24

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML

This description comes directly from the study's public registry record.

Talk to the study team

He Huang, MD · +8613605714822 · hehuangyu@126.com

Yongxian Hu, MD · +8615957162012 · huyongxian2000@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (1)

the First Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06367673